Skip to content

Intima Media Thickness Regression in Dyslipidemic Teenagers

Intervention précoce Sur Les Indices d'athérogénèse Des Adolescents à Risque

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01768481
Enrollment
16
Registered
2013-01-15
Start date
2004-01-31
Completion date
2010-06-30
Last updated
2013-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia, Obesity

Keywords

Obesity, Dyslipidemia, Cholesterol, Intima media thickness

Brief summary

Randomized controlled trial of statin intervention in dyslipidemic obese teenagers. Primary outcome is intima media thickness before and after intervention.

Detailed description

Obese teenagers with abnormal lipid profiles were randomized to either low dose statin or placebo and had their carotid intima media thickness compared before and after intervention.

Interventions

DRUGAtorvastatin

10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year

DRUGsugar pill

placebo controlled arm receives similarly looking placebo.

Sponsors

Pfizer
CollaboratorINDUSTRY
Université de Montréal
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
14 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Obesity * Abnormal Triglyceride levels (\>1.7mmol/L). * Abnormal HDL-C levels (1.0mmol/L)

Exclusion criteria

* Abnormal thyroid unfction (not treated) * Diabetes

Design outcomes

Primary

MeasureTime frameDescription
carotid intima media thickness12 monthsCarotid Intima media thickness measured at baseline and after 12 months in 2 arms (placebo and statin)

Secondary

MeasureTime frameDescription
weight12 monthsweight, height and BMI recorded before and after intervention

Other

MeasureTime frameDescription
BMI12 monthsBMI neasured at baseline and at end of study
Lipid profile6 monthsComplete lipid profile were recorded at baseline , 6 months and 12 months after intervention.
creatinine kinase3 monthsCK done at 3 , 6, 9 and 12 months
liver functions3 monthsALT/AST done at 3, 6, 9 and 12 months
lipid profile12 monthsLipid profile measured at end of study

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026